Brief: UNITY Biotechnology Completes Enrollment in Phase 2 Study of UBX1325 in Diabetic Macular Edema
12/04/2022 13:11
April 12 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY COMPLETES ENROLLMENT IN BEHOLD, THE
PHASE 2
STUDY OF SENOLYTIC CANDIDATE UBX1325 IN DIABETIC MACULAR EDEMA
* UNITY BIOTECHNOLOGY INC - 12-WEEK SAFETY AND EFFICACY DATA
ANTICIPATED BY MID-YEAR 2022
* UNITY BIOTECHNOLOGY INC - 24-WEEK SAFETY AND EFFICACY DATA
ANTICIPATED BEFORE YEAR-END 2022
Source text for Eikon: ID:nGNX3FYlCQ
Further company coverage: UBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force